InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research note released on Tuesday. The firm issued a sell rating on the stock.

Separately, Piper Sandler reiterated an “overweight” rating and set a $4.50 price objective on shares of InspireMD in a research note on Tuesday, September 17th.

InspireMD Stock Down 3.3 %

Shares of NYSE:NSPR opened at $2.92 on Tuesday. The business’s 50 day moving average is $2.59 and its 200 day moving average is $2.63. The stock has a market cap of $76.15 million, a price-to-earnings ratio of -3.89 and a beta of 0.93. InspireMD has a 12-month low of $1.81 and a 12-month high of $3.42.

InspireMD (NYSE:NSPR) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. The firm had revenue of $1.81 million during the quarter, compared to the consensus estimate of $1.74 million. During the same quarter in the prior year, the company earned ($0.15) EPS. As a group, equities research analysts expect that InspireMD will post -0.79 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NSPR. Rosalind Advisors Inc. lifted its stake in InspireMD by 266.4% in the second quarter. Rosalind Advisors Inc. now owns 2,513,641 shares of the company’s stock worth $6,272,000 after purchasing an additional 1,827,579 shares during the last quarter. Affiance Financial LLC bought a new position in InspireMD in the 3rd quarter worth $492,000. Finally, Parkman Healthcare Partners LLC purchased a new stake in InspireMD in the third quarter worth about $279,000. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.